An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasized, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase 3 clinical trial. The study showed that overall survival was 2 - 3 times higher than in the placebo arm.
from Top Health News -- ScienceDaily https://ift.tt/36pcpYj
No comments:
Post a Comment